KYNB:NASDAQ
Kyntra Bio Inc
$6.90
arrow_downward
-1.84%(-0.13) 1D
May 29, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KYNB...
Open
$7.05
High
$7.05
Low
$6.86
Mkt. cap
27.93M
Avg. vol.
7.82K
Volume
6.65K
P/E ratio
0.17
52-wk high
$9.70
52-wk low
$6.32
EPS
$40.46
Beta
1.04
Shares outstanding
4.05M
No. of employees
34
Open
$7.05
High
$7.05
Low
$6.86
Mkt. cap
27.93M
Avg. vol.
7.82K
Volume
6.65K
P/E ratio
0.17
52-wk high
$9.70
52-wk low
$6.32
EPS
$40.46
Beta
1.04
Shares outstanding
4.05M
No. of employees
34
News stories
From sources across the web
The Legal Advocate
·
1 month ago
Kyntra Bio (KYNB) Stock Breakout Trade (Bearish Sentiment) 2026-04-20 - ETF Flow
Profile
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
About Kyntra Bio Inc
CEO-
Employees34
FoundedJan 1, 1993
HeadquartersSan Francisco, California, United States
SectorBiotechnology
Websitefibrogen.com
AI content may include mistakes. Learn more